Series A - Shinobi Therapeutics
Investment Firm
Overview
Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment.
Announced Date
Dec 12, 2023
Closed on Date
Dec 12, 2023
Funding Type
Series A
Highlights
Location
United States, North America
Social
Investor Lead
EQT Life Sciences
EQT Life Sciences is a debt and early_stage_venture and late_stage_venture and post_ipo and venture firm.
F-Prime Capital
F-Prime Capital is a early_stage_venture and late_stage_venture and seed and venture firm.
Eight Roads Ventures Japan
Eight Roads Ventures Japan is a early_stage_venture firm.
Participant Investors
6
Round Details and Background
Shinobi Therapeutics raised $51000000 on 2023-12-12 in Series A
Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment.
Company Funding History
3
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Dec 12, 2023 |  Series A - Shinobi Therapeutics | 7 | - | 51.0M |
| Aug 06, 2024 | Grant - Shinobi Therapeutics | 1 | - | 59.0M |
| Aug 06, 2024 | Series A - Shinobi Therapeutics | 2 | - | 68.0M |
Recent Activity
There is no recent news or activity for this profile.